• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconPharmaceutical Industry

Pharmaceutical Industry

Page 88 of 100
BRITAIN-PHARMA-BUSINESS-ASTRAZENECA
HealthAstrazeneca is Buying ZS Pharma for $2.7 billion
By Laura LorenzettiNovember 6, 2015
Walgreens-Rite Aid deal could lead to elimination of 3,000 stores
RetailWalgreens-Rite Aid deal could lead to elimination of 3,000 stores
By Phil WahbaNovember 5, 2015
MSMB Capital Management CIO Martin Shkreli
HealthTuring Says it Will Lower Daraprim Price by the End of the Year
By Laura LorenzettiNovember 4, 2015
Fortune Global Forum 2015
HealthHow the U.S. Subsidizes Europe’s Health Care Costs
By Beth KowittNovember 3, 2015
Hedge fund manager Bill Ackman
FinanceBill Ackman on Valeant: ‘Life will go on’
By Stephen GandelOctober 30, 2015
J. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc., waits for the start of their annual general meeting in Laval, Quebec
HealthValeant cuts ties to controversial pharmacy chain Philidor
By Geoffrey SmithOctober 30, 2015
Hedge fund manager Bill Ackman
FinanceAnother one of Bill Ackman’s top stocks is down 50%
By Jen WiecznerOctober 29, 2015
A Starbucks cafe in Sanlitun. For the third quarter of 2015
FeaturesPharma megadeal and Starbucks earnings — 5 things to know today
By Tom Huddleston Jr. and Geoffrey SmithOctober 29, 2015
Allergan Inc.'s Botox Cosmetic As Actavis Plc Buys Drugmaker For $66 Billion
HealthWhen Viagra met Botox: Pfizer, Allergan eye mega-merger
By Geoffrey SmithOctober 29, 2015
Cholesterol lowering pill
HealthThis drug will make your flu shot less effective
By TIMEOctober 29, 2015
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
FinanceValeant accounting scandal: 4 critical questions that have been left unanswered
By Stephen GandelOctober 26, 2015
Why the drug price scandal won’t be enough to keep down prices
RetailWhy the drug price scandal won’t be enough to keep down prices
By Laura LorenzettiOctober 26, 2015
Imprimis Turing Drug
HealthThis company is offering a $1 alternative to Turing’s $750 drug
By Laura LorenzettiOctober 23, 2015
MSMB Capital Management CIO Martin Shkreli
HealthThis super-expensive drug is getting a $1 rival
By Benjamin SnyderOctober 23, 2015
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
FinanceValeant short seller on pharmacy alliance: It’s the ‘turd in the punch bowl’
By Stephen GandelOctober 22, 2015
1...
  • 86
  • 87
  • 88
  • 89
  • 90
...100
Most Popular
Future of Work
'Employers are increasingly turning to degree and GPA' in hiring: Recruiters retreat from ‘talent is everywhere,’ double down on top collegesplaceholder alt text
By Jake AngeloMay 9, 2026
Politics
Ted Cruz says the quiet part out loud: Trump accounts are Social Security personal accounts as GOP senator reveals 'dirty little secret'placeholder alt text
By Jason MaMay 9, 2026
Success
Red flag test: former CEO explains why he rejects job candidates who say they can start right awayplaceholder alt text
By Orianna Rosa RoyleMay 9, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.